BioSpace News Archive

United Therapeutics Corporation announced that it will report its second quarter 2021 financial results before the market opens on Wednesday, August 4, 2021.

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended June 30, 2021.

Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, August 4, 2021, at 8:00 a.m. ET to provide a corporate update and results for the second quarter of 2021.

Bristol Myers SquibbBristol Myers SquibbBristol Myers Squibb reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company.

RELIEF THERAPEUTICS Holding AG reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., reported in a press release yesterday that the Nation of Georgia’s Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous aviptadil for the treatment of critical COVID-19.

Inceptor Bio, a Research Triangle Park, North Carolina-based cell and gene therapy biotechnology company, announced the appointment of Dr. Mark J. Gilbert as Chair of its Scientific Advisory Board – leading a team of cell and gene therapeutics experts as scientific advisors to the company.

The global clinical rollators market has witnessed steady growth over the years with the rising technological advancements in developing rollator walker with lightweight and seat rollators.

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that it will report its second quarter 2021 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021.

BioCryst Pharmaceuticals, Inc. announced that the company has appointed hereditary angioedema and rare disease industry leader, Vincent Milano, to its board of directors.